This multicenter , double-blind , placebo-controlled , repeat treatment , 7-month study randomized subjects with moderate-to-severe CFL and GL ( maximum contraction ) to onabotulinumtoxinA 44 U ( CFL : 24 U , GL : 20 U ; n = 305 ) , onabotulinumtoxinA 24 U ( CFL : 24 U , GL : placebo ; n = 306 ) , or placebo ( n = 306 ) .